Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinska AkadfiledCriticalMedizinska Akad
Priority to BG9134090ApriorityCriticalpatent/BG50104A1/en
Publication of BG50104A1publicationCriticalpatent/BG50104A1/en
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Abstract
The hybridoma cell line applies to oncology. It has a high productivity in vitro, and the use of its secreted monoclonal antibody increases the degree of detection of the antigen determinant NOC-1. The line is created by fusion of splenocytes from immunized melanoma cells from mice, line BALB/c - with mouse myelin cells of the line P3x63 Ag 8.653 and is registered in NBPMKK under 216 1682.
BG9134090A1990-03-011990-03-01Hybridome cell line, secretting monoclonal antibody against antigene determinante noc- 1 of malignant melanom in human
BG50104A1
(en)
MONOCLONAL ANTIBODIES AND PRODUCTION OF A VACCINE AGAINST HUMAN CANCER ANTIGENS BY IMMUNIZATION WITH HUMAN AND ANIMAL MUCIN AND WITH SYNTHETIC GLUCIDEN CARRIER CONJUGATES.
Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenic deternimant, common for the strains hantaan and finnish of the virus of haemorrhagic fever with nephritic syndrome
Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome